The Claim
In old male mice, a 4-week anti-myostatin antibody treatment reduced intramuscular triglyceride content by approximately 30% without changing hepatic triglyceride levels, indicating a tissue-specific effect on lipid metabolism in skeletal muscle.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In older male mice, a 4-week treatment with an anti-myostatin antibody lowered fat levels inside muscle tissue by about 30% but did not change fat levels in the liver.
See the scientific wording
In old male mice, a 4-week anti-myostatin antibody treatment reduced intramuscular triglyceride content by approximately 30% without changing hepatic triglyceride levels, suggesting a tissue-specific effect on lipid metabolism in skeletal muscle.
Blocking myostatin makes muscle fibers grow larger, which increases the muscle's ability to burn fat for energy. As a result, the fat stored inside the muscle decreases, but fat in the liver stays the same because the liver is not affected by this process.
What the research says
1 studyIn older male mice, a treatment that blocks a protein called myostatin made muscles bigger and stronger, and also cut down the fat inside the muscles by 30%—but didn’t change the fat in the liver. This means the treatment only affected the muscles, not the liver.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.